AR and prostate carcinoma: How treatment resistance emerges under the selective pressure of systemic therapy is a topic of intense speculation.32 Certainly, current evidence suggests that selection of subclones harboring genomic variants offering a pro-survival advantage is the predominant mechanism of prostate cancer persistence following intense AR signaling inhibition.